양성자펌프억제제에 반응하지 않는 인두이물감 환자에서 “뮤코미스트Mucomyst®” 객담제거 및 상기도 염증치료를 통한 증상개선효과 평가 다기관, 단일군, 전향적 관찰 연구 = Multi-Institute, Single Group, Prospective Observational Study to Evaluate the Efficacy of Mucomyst® in Relieving Symptoms of Globus Pharyngeus Refractory to Proton Pump Inhibitor

다국어 초록 (Multilingual Abstract)

Background and Objectives Globus pharyngeus is one of the most common symptoms of patients visiting otorhinolaryngology out-patient clinic, and usually long-lasting, difficult to treat, and frequently recurrent. Mucomyst®, N-acetyl cysteine is an inhalation agent mainly used for mucolysis and reducing inflammation in airway via antioxidative effect. The purpose of this study was to evaluate the efficacy of inhaled Mucomyst® treatment in patients with globus pharyngeus refractory to proton pump inhibitor (PPI).Materials and Method We prospectively evaluated the efficacy of Mucomyst® in relieving symptoms of globus pharyngeus refractory to PPI in nine medical centers. Three hundred and three patients enrolled and finally 229 patients finished the inhaled Mucomyst® therapy for 8 weeks. We analyzed the change of Reflux Symptom Index (RSI), Reflux Finding Score (RFS), Visual Analogue Scale (VAS) for globus, and Globus Pharyngeus Symptom Scale (GPS) after use of Mucomyst® for 4 and 8 weeks.Results The GPS, RSI, RFS, and VAS score significantly decreased serially in patients who finished 8 week-inhalation treatment. The GPS improvement gap was significantly correlated with initial GPS (p<0.001) in multiple regression analysis.Conclusion Inhaled Mucomyst® therapy was effective for the reduction of both subjective and objective findings in refractory globus patients. This study might suggest new treatment option for patients with globus. However, further thorough studies would be needed to assess the real effect of inhaled Mucomyst® treatment as a standard treatment for globus.

참고문헌 (Reference)

1 Belafsky PC, "Validity and reliability of the reflux symptom index(RSI)" 16 (16): 274-277, 2002

2 Kwan AC, "Validation of Rome II criteria for functional gastrointestinal disorders by factor analysis of symptoms in Asian patient sample" 18 (18): 796-802, 2003

3 Belafsky PC, "The validity and reliability of the reflux finding score(RFS)" 111 (111): 1313-1317, 2001

4 Khalil HS, "The use of speech therapy in the treatment of globus pharyngeus patients. A randomised controlled trial" 124 (124): 187-190, 2003

5 Selleslagh M, "The complexity of globus : A multidisciplinary perspective" 11 (11): 220-233, 2014

6 Khalil HS, "Speech therapy in the treatment of globus pharyngeus : How we do it" 36 (36): 388-392, 2011

7 Millea PJ, "N-acetylcysteine : Multiple clinical applications" 80 (80): 265-269, 2009

8 Calzetta L, "Multifaceted activity of N-acetyl-l-cysteine in chronic obstructive pulmonary disease" 12 (12): 693-708, 2018

9 Harvey PR, "Managing a patient with globus pharyngeus" 9 (9): 208-212, 2018

10 Deary IJ, "Globus pharyngis : Development of a symptom assessment scale" 39 (39): 203-213, 1995

11 Kirch S, "Globus pharyngeus : Effectiveness of treatment with proton pump inhibitors and gabapentin" 122 (122): 492-495, 2013

12 Lee BE, "Globus pharyngeus : A review of its etiology, diagnosis and treatment" 18 (18): 2462-2471, 2012

13 Järvenpää P, "Globus pharyngeus : A review of etiology, diagnostics, and treatment" 275 (275): 1945-1953, 2018

14 Tang B, "Clinical-psychological characteristics of refractory globus patients in China" 48 (48): 381-384, 2016

15 Bouchoucha M, "Clinical and psychological characteristics of patients with globus" 43 (43): 614-622, 2019

16 전혜경 ; 김광하 ; 최문기 ; 정재훈 ; 백동훈 ; 이광재 ; 이항미 ; 이봉은 ; 송근암, "Clinical Predictors for Response to Proton Pump Inhibitor Treatment in Patients With Globus" 대한소화기 기능성질환∙운동학회 19 (19): 47-53, 2013

17 Park SJ, "Antioxidants as novel agents for asthma" 6 (6): 235-240, 2006